其 他 安 全 警 示
|
| |
| The United Kingdom: Class 4 Medicines Defect Information: OxyContin 20 mg prolonged release tablets (English only) |
| |
Medicines and Healthcare products Regulatory Agency (MHRA) announces that Napp Pharmaceuticals Limited has identified an error relating to the Braille printed on the cartons of 2 batches of OxyContin 20 mg prolonged release tablets (oxycodone hydrochloride) (batch number: 250630, 250869). The Braille message on the OxyContin 20 mg prolonged release tablets incorrectly states strength as 15 mg.
The impacted products are within specification and there is no issue with product quality. Therefore, the affected batches are not being recalled.
Healthcare professionals should confirm when dispensing this product if this medicine is being collected on behalf of somebody else or if the patient will solely rely on Braille, and if needed explain the error in the Braille.
Please refer to the following website in MHRA for details:
http://www.gov.uk/drug-device-alerts/class-4-medicines-defect-information-oxycontin-20-mg-prolonged-release-tablets-el-22-a-slash-27
In Hong Kong, Oxycontin Prolonged Release Tab 20mg (HK-59574) is a pharmaceutical product registered by Mundipharma (Hong Kong) Limited (Mundipharma). The product is a prescription-only medicine. As confirmed with Mundipharma, the affected batches have not been imported into Hong Kong.
Ends/Thursday, Jun 2, 2022
Issued at HKT 15:00
|
| |
